Share-based Compensation (Tables)

9 Months Ended

Dec. 31, 2021

Summary of share-based compensation expense for options

The following table summarizes the share-based compensation expense for SSARs, restricted and performance grants included in the condensed consolidated statements of operations:

	Three Months Ended December 31,				Nine Months Ended December 31,
(In thousands)	2021		2020		2021		2020
Product development	$	2,217	$	3,362	$	6,033	$	3,773
Sales and marketing		345		666		1,011		735
General and administrative		1,277		2,602		3,758		4,804
Total share-based compensation expense	$	3,839	$	6,630	$	10,802	$	9,312

Activity related SSARs award

The following table summarizes the activity during the nine months ended December 31, 2021 for SSARs awarded under the 2020 and 2016 Plans:

	Number of Rights			Weighted-Average Exercise Price		Remaining Contractual Term		Aggregate Intrinsic Value
				(per right)		(in years)		(in thousands)
Outstanding at April 1, 2021		3,068,253		$	20.90
Exercised		(820,341	)		12.72
Forfeited		(49,750	)		20.02
Expired		(246	)		14.22
Outstanding at December 31, 2021		2,197,916		$	23.97		4.9	$	45,041
Exercisable at December 31, 2021		1,262,704		$	23.54		4.7	$	26,421
Vested and expected to vest at December 31, 2021		2,197,916		$	23.97		4.9	$	45,041

The following table summarizes the activity during the nine months ended December 31, 2021 for restricted shares awarded under the 2020 and 2016 Plans:

	Number of Shares			Weighted-Average Grant-Date Fair Value
				(per share)
Outstanding at April 1, 2021		132,198		$	37.67
Granted		108,473			43.77
Vested		(1,056	)		52.29
Forfeited		(8,416	)		37.66
Outstanding at December 31, 2021		231,199		$	40.34